BRIC Digital Physician Study: Physician Digital Behaviors Unique Across Countries

BRIC Digital Physician Study: Physician Digital Behaviors Unique Across Countries

Stephanie Cooper, 212-255-1368

Pharma companies looking to leverage digital channel to boost sales and marketing must refine their understanding of the digital profiles of physicians in these countries. According to the Taking the Pulse BRIC study from firm Manhattan Research, physician use of the Internet during the workday is comparatively high in Brazil, moderate in India, and less pervasive in China.

“Physicians’ digital professional profiles vary market-to-market, whether we look at the use of mobile devices between consultations and at the point of care, or the kinds of social networks relied on,” said Principal Analyst James Avallone at Manhattan Research. “Country-specific knowledge is needed to prioritize tactics and investments.”

Taking the Pulse BRIC is a market research and advisory service focused on how physicians in Brazil, Russia, India and China use digital media and devices for , with the objective of helping global marketers assess opportunities for providing content, services and support to physicians online.

If you would like to download a complimentary infographic of key trends among global physicians, please visit .

The Taking the Pulse Global Series explores digital adoption trends among online physicians in Australia (new this year), Turkey (new this year), Brazil, Mexico , Russia, Canada, the United States, Germany, France, Spain, Italy, the United Kingdom, China, South Korea, India, Japan and Taiwan.

For more information, please visit , email or call 1.888.680.0800, ext 2.

Manhattan Research, a Decision Resources Group company, conducts annual research studies covering digital health trends among healthcare professionals and consumers in the Americas, Europe, and Asia-Pacific. Broad research can be segmented by target specialist and therapeutic audiences. For more information please contact , call 1.888.680.0800, ext 2, or visit .

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.